o a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number				
Filing Date		2006-05-15		
First Named Inventor Tak V		Wai CHEUNG		
Art Unit				
Examiner Name				
Attorney Docket Numb	er	102792-214/11363P3US		

U.S.PATEN				PATENTS	S Remove		
Examiner Initial*	er Cite No Patent Number		Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	
	1	4246129		1981-01-20	Kacher		
	2	4269723		1981-05-26	Barford et al.		
	3	4043931		1977-08-23	Jeffrey et al.		
	4	4460490		1984-07-17	Barford et al.		
	5	4722802		1988-02-02	Hutchings et al.		
	6	4820449		1989-04-11	Menke et al.		
	7	5342550	A	1994-08-30	Bunke et al.		
	8	5562850	А	1996-10-08	Woo et al.		

	Application Number			_
NEODMATION DIOCE COURT	Filing Date		2006-05-15	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Tak V		Wai CHEUNG	
Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Number		102792-214/11363P3US	

		9	5711920	A	1998-01-27	Barford et al.		
		10	5759974	A	1998-06-02	Menke et al.		
		11	5939372	A	1999-08-17	Schmid et al.		
		12	6001789	A	1999-12-14	Trinh et al.		
		13	6294510	B1	2001-09-25	Russell et al.	Column	n 3, line 14 line 54; claims; le 1
		14	4738728	А	1988-04-19	Barford et al.	Column	n 2, line 33 – line 54; claims; les
		15	6255268	B1	2001-07-03	Counts	Column 1; clain	n 8, line 32 - column 10, line ns; examples
		16	5449473	A	1995-09-12	Bunczk et al.		n 3, line 21 column 4, line ims; examples
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS Remove								Remove
	Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where int Passages or Relevant s Appear
		1	20030156976	A1	2003-08-21	Wilson et al.		aphs '0001!, '0002!, '0005!, '0010! '0012!, '0020!,

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		
	Filing Date		2006-05-15
	First Named Inventor Tak V Art Unit Examiner Name Attorney Docket Number		Vai CHEUNG
			102792-214/11363P3US

Pages Columns Lines

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Applicant of cited Document	where Relevant Passages or Relevant Figures Appear	T5
	1	2288814	GB	A	1995-11-01	Jeyes	See in particular paragraph 2, page 3 and paragraph 2, page 5	
	2	94/12612	wo	A1	1994-06-09	Jeyes Group PLC	Page 5, line 6 line 26; claims; examples 5, 7	
	3	00/23558	wo	A1	2000-04-27	Jeyes Group Limited	Page 2, line 1 line 21; claims; examples	
	4	98/41608	wo	A1	1998-09-24	Unilever PLC	Page 7, line 31 page 8, line 2; claims	
	5	98/47998	wo	A1	1998-10-29	S.C. Johnson & Son, Inc.	Page 2, line 8 page 3, line 11; claims; examples 2-6	
	6	0526437	EP	A	1993-02-03	Kiwi Brands Inc.	Claims; examples	
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	miner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, diy androu country where published.						T5	
	Copy of Combined Search and Examination Report from The Patent Office in Great Britain dated May 28, 2004 for application GB0327688 1							
	2	Copy of the International	al Search Report d	lated Fel	bruary 2, 2005 f	or application PCT/GB2004	/004862	

FOREIGN PATENT DOCUMENTS

	Application Number			
NEODMATION DIOCE COURT	Filing Date		2006-05-15	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Tak V	Vai CHEUNG	
Not for submission under 37 CFR 1.99)	Art Unit			_
Not for Submission and of or it 1.50y	Examiner Name			
	Attorney Docket Numb	er	102792-214/11363P3US	

3	Copy of the Written Opinion of the International Searching Authority for application PCT/GB2004/004862	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See first Codes of USPTO Patent Documents at swer_USPET_OGO(or MEPE 9619.4. 2 linker office that issued the document, by the involved on (WPO-Standard ST3). First planarees patent documents, the origination of the year of the register of the Department precise the sent annual replicated to the part document.

**Ind of document by the appropriate symbols as endicated on the document under WIPO Standard ST3.16 if possible. 2 Applicant is to place a check mark here if English languages precisions in standard.

Application Number Filing Date 2006-05-15 Fish Date 2006-05-15 First Named Inventor Tak War CHEUNG Art Unit Examiner Name Attorney Docket Number 102/792-214/11353/3US

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and	a 1.36 to make the appropriate selection(s):	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eV1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/Andrew N. Parfomak/	Date (YYYY-MM-DD)	2006-05-15
Name/Print	Andrew N. Parfornak	Registration Number	32431

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolffice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.